{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010313","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.875674+00:00","generated_at":"2026-06-17T13:25:52.405431+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics reports FY2022 revenue $6.7M, net loss $14.9M; cash $32M","bullets":["Q4 2022 revenue $1.3M from licensed molecule sale to Wugen; full year $6.7M (nil in prior year).","R&D expenses $9.3M for FY2022 (vs $8.2M), G&A $8.3M (vs $5.2M); net loss $14.9M (vs $12.9M).","Cash, cash equivalents & short-term investments total $32.0M as of Dec 31, 2022; funding sufficient through next 12 months.","Phase 1/1b trials for HCW9218 in solid tumors and advanced pancreatic cancer ongoing; Phase 1 completion targeted in 2023.","CRADA with NCI for Phase 1b/2 pancreatic study; scientific paper on HCW9302 published in Frontiers in Immunology."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010313","json":"https://secwatch.observer/filing/0000950170-23-010313.json","markdown":"https://secwatch.observer/filing/0000950170-23-010313.md","text":"https://secwatch.observer/filing/0000950170-23-010313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/hcwb-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:25:52.405431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"417b8456dac3e27dae2b8280c89859d92a6f0c63","claim":"HCW Biologics Inc. reported the year ended December 31, 2022 results: revenue $6.7 million.","evidence_excerpt":"Revenues for the year ended December 31, 2021 and 2022 were nil and $6.7 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$6.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7dc4d8799d080a8bcbb1d90caf12e4490d29bc72","claim":"HCW Biologics Inc. reported the fourth quarter ended December 31, 2022 results: revenue $1.3 million.","evidence_excerpt":"Revenues for the fourth quarter ended December 31, 2021 and 2022 were nil and $1.3 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$1.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}